• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTO alert in real time by email

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets.

    Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising significant capital. Christina Ackermann succeeds Harry Welten, who resigns after six years on the Board of Directors.

    "Christina and Tim are exceptional leaders. Their broad expertise across commercial and legal affairs as well as their network among investors will be key as we prepare for the next development steps of our serotype-independent vaccine candidates," said Anna Sumeray, CEO of Virometix. "We look forward to working with Christina and Tim and we will greatly benefit from their business acumen and broad networks as we advance our pipeline towards the next key milestones. I would like to thank Harry for his dedication and guidance as Chair over the last five years."

    Christina Ackermann brings over 27 years of legal and management experience across the pharmaceutical, device, and consumer products industries. Ms. Ackermann was instrumental in establishing various global legal functions, strategic initiatives, and transactions at Bausch + Lomb, Novartis, Bristol-Myers Squibb, and DuPont. She currently serves as a non-executive member of the boards of Verona Pharma plc (NASDAQ:VRNA), Oculis Holding AG (NASDAQ:OCS), and private boards/NGOs. Ms. Ackermann holds a Post Graduate Diploma in EC Competition Law from King's College at the University of London, UK, and an LLB from Queen's University, Kingston, Canada.

    Tim Ramdeen has nearly a decade of experience in private equity, hedge fund investing, capital markets, and company formation. Since 2022, Mr. Ramdeen has been the founder and managing partner of Dharma Capital Advisors. Mr. Ramdeen currently serves as a non-executive member of the boards of Onconetix Inc. (NASDAQ:ONCO) and Entero Therapeutics Inc. (NASDAQ:ENTO). He received his B.S. in Biology from Temple University. Additionally, Mr. Ramdeen earned his MBA in Finance from the NYU Stern School of Business.

    About Virometix

    Virometix AG is a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer. There is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix' proprietary "Synthetic Virus-Like Particle" platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy, ease and cost of manufacturing and stability.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241002541613/en/

    Get the next $ENTO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTO
    $OCS
    $ONCO
    $VRNA

    CompanyDatePrice TargetRatingAnalyst
    Oculis Holding AG
    $OCS
    8/27/2025$36.00Buy
    Needham
    Verona Pharma plc
    $VRNA
    7/14/2025Buy → Neutral
    H.C. Wainwright
    Verona Pharma plc
    $VRNA
    7/1/2025$170.00Outperform
    Wolfe Research
    Verona Pharma plc
    $VRNA
    4/28/2025$100.00Buy
    TD Cowen
    Verona Pharma plc
    $VRNA
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    Verona Pharma plc
    $VRNA
    1/10/2025$68.00Buy
    ROTH MKM
    Verona Pharma plc
    $VRNA
    10/3/2024$50.00Overweight
    Wells Fargo
    Oculis Holding AG
    $OCS
    12/5/2023$30.00Buy
    Chardan Capital Markets
    More analyst ratings

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Fisher Andrew returned 1,349,887 units of Ordinary Shares to the company and converted options into 931,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    10/8/25 4:45:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Zaccardelli David returned 15,461,424 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    10/8/25 4:44:12 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rickard Kathleen A. returned 3,564,852 units of Ordinary Shares to the company and converted options into 1,131,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    10/8/25 4:43:18 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Oculis Holding AG with a new price target

    Needham initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $36.00

    8/27/25 8:25:52 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Verona Pharma from Buy to Neutral

    7/14/25 8:43:04 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Verona Pharma with a new price target

    Wolfe Research initiated coverage of Verona Pharma with a rating of Outperform and set a new price target of $170.00

    7/1/25 8:22:56 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring develop

    10/7/25 8:00:00 AM ET
    $ENGN
    $GTBP
    $IMAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Merck Completes Acquisition of Verona Pharma

    Acquisition strengthens Merck's cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma") acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market. "The Verona Pharma acquisition strengthens and complements our portfolio of treatments for patients with cardio-pulmonary diseases to include Ohtuvayr

    10/7/25 6:45:00 AM ET
    $MRK
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

    LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the proposal for MSD to acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $1

    10/6/25 4:05:00 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    $OCS
    $ONCO
    $VRNA
    SEC Filings

    View All

    SEC Form 144 filed by Oculis Holding AG

    144 - Oculis Holding AG (0001953530) (Subject)

    10/9/25 4:22:39 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Onconetix Inc.

    D - Onconetix, Inc. (0001782107) (Filer)

    10/7/25 5:14:02 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Verona Pharma plc

    S-8 POS - Verona Pharma plc (0001657312) (Filer)

    10/7/25 1:03:40 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/18/24 4:20:05 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/7/24 6:57:21 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/7/24 6:56:12 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

    Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company f

    8/25/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Publishes Invitation to the Annual General Meeting

    ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

    5/9/25 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entero Therapeutics Appoints Richard Paolone as CEO

    BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt

    2/14/25 4:00:00 PM ET
    $ENTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Financials

    Live finance-specific insights

    View All

    Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

    Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophtha

    10/6/25 4:07:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

    4/29/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

    LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

    4/15/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oculis Holding AG

    SC 13G - Oculis Holding AG (0001953530) (Subject)

    12/9/24 9:43:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 5:46:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 4:50:28 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care